Cargando…

How to target small cell lung cancer

Small cell lung cancer (SCLC) is a highly malignant disease with dismal prognosis. Although great progress has been made in investigating genetic aberrations and putative drivers of this tumor entity, the mechanisms of rapid dissemination and acquisition of drug resistance are not clear. The majorit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hamilton, Gerhard, Rath, Barbara, Ulsperger, Ernst
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Research Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4580060/ https://www.ncbi.nlm.nih.gov/pubmed/26425658

Ejemplares similares

Effects of salinomycin and niclosamide on small cell lung cancer and small cell lung cancer circulating tumor cell lines
por: Hochmair, Maximilian, et al.
Publicado: (2019)

Expression of Proteolytic Enzymes by Small Cell Lung Cancer Circulating Tumor Cell Lines
por: Rath, Barbara, et al.
Publicado: (2019)

Small cell lung cancer: circulating tumor cell lines and expression of mediators of angiogenesis and coagulation
por: Rath, Barbara, et al.
Publicado: (2023)

Small cell lung cancer: model of circulating tumor cell tumorospheres in chemoresistance
por: Klameth, Lukas, et al.
Publicado: (2017)

Non-small cell lung cancer-small cell lung cancer transformation as mechanism of resistance to tyrosine kinase inhibitors in lung cancer
por: Rath, Barbara, et al.
Publicado: (2020)

Comparison of the effects of the oral anticancer platinum(IV) complexes oxoplatin and metabolite cis-diammine-tetrachlorido-platinum(IV) on global gene expression of NCI-H526 cells
por: Olszewski, Ulrike, et al.
Publicado: (2011)

Receptor tyrosine kinase expression of circulating tumor cells in small cell lung cancer
por: Hamilton, Gerhard, et al.
Publicado: (2015)

Anticancer Activity of Fascaplysin against Lung Cancer Cell and Small Cell Lung Cancer Circulating Tumor Cell Lines
por: Rath, Barbara, et al.
Publicado: (2018)

Synergism of Cyclin-Dependent Kinase Inhibitors with Camptothecin Derivatives in Small Cell Lung Cancer Cell Lines
por: Hamilton, Gerhard, et al.
Publicado: (2014)

Epigenetic reprogramming in small cell lung cancer
por: Chen, Jingyao, et al.
Publicado: (2022)

Cytotoxicity of combinations of the pan-KRAS inhibitor BAY-293 against primary non-small lung cancer cells
por: Plangger, Adelina, et al.
Publicado: (2021)

Changes of protein expression during tumorosphere formation of small cell lung cancer circulating tumor cells
por: STICKLER, SANDRA, et al.
Publicado: (2023)

In Vitro Evaluation of Oxoplatin: An Oral Platinum(IV) Anticancer Agent
por: Olszewski, Ulrike, et al.
Publicado: (2009)

Significance of circulating tumor cells in lung cancer: a narrative review
por: Hamilton, Gerhard, et al.
Publicado: (2023)

In vitro cytotoxicity of combinations of dichloroacetate with anticancer platinum compounds
por: Olszewski, Ulrike, et al.
Publicado: (2010)

Therapeutic revolution for inoperable stage III non-small cell lung cancer in the immune era
por: Li, Jiakang, et al.
Publicado: (2022)

Repositioning canakinumab for non-small cell lung cancer—important lessons for drug repurposing in oncology
por: Lythgoe, Mark P., et al.
Publicado: (2022)

A Systems Biology Approach for Addressing Cisplatin Resistance in Non-Small Cell Lung Cancer
por: Ramisetty, Sravani, et al.
Publicado: (2023)

Spotlight on Tepotinib and Capmatinib for Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation
por: Brazel, Danielle, et al.
Publicado: (2022)

Neoadjuvant checkpoint inhibition in non-small cell lung cancer: Is earlier unquestionably better than later?
por: Olivier, Timothée, et al.
Publicado: (2022)

How the histological structure of some lung cancers shaped almost 70 years of radiobiology
por: Worth, Katja R., et al.
Publicado: (2022)

How Can the EU Beating Cancer Plan Help in Tackling Lung Cancer, Colorectal Cancer, Breast Cancer and Melanoma?
por: Horgan, Denis, et al.
Publicado: (2022)

Synergistic cytotoxicity of the CDK4 inhibitor Fascaplysin in combination with EGFR inhibitor Afatinib against Non-small Cell Lung Cancer
por: Plangger, Adelina, et al.
Publicado: (2021)

EGFR Inhibition in Non-Small Cell Lung Cancer: Resistance, Once Again, Rears Its Ugly Head
por: Clark, Jennifer, et al.
Publicado: (2005)

Small Molecule KRAS Inhibitors: The Future for Targeted Pancreatic Cancer Therapy?
por: Gillson, Josef, et al.
Publicado: (2020)

How informative is a negative finding in a small pharmacogenetic study?
por: Bacanu, S-A, et al.
Publicado: (2012)

Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer
por: Manegold, Christian, et al.
Publicado: (2012)

BCL-2 inhibition is a promising therapeutic strategy for small cell lung cancer
por: Lochmann, Timothy L, et al.
Publicado: (2018)

A Canadian Perspective on the Challenges for Delivery of Curative-Intent Therapy in Stage III Unresectable Non-Small Cell Lung Cancer
por: Brade, Anthony, et al.
Publicado: (2021)

Small molecules to target tau amyloid aggregation
por: Manglano-Artuñedo, Zoe, et al.
Publicado: (2023)

How inclusive are cell lines in preclinical engineered cancer models?
por: Raghavan, Shreya
Publicado: (2022)

Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes
por: Palma, Gabriela, et al.
Publicado: (2021)

Cytotoxic Effects of Fascaplysin against Small Cell Lung Cancer Cell Lines
por: Hamilton, Gerhard
Publicado: (2014)

How to Get the Most from Methotrexate (MTX) Treatment for Your Rheumatoid Arthritis Patient?—MTX in the Treat-to-Target Strategy
por: Taylor, Peter. C., et al.
Publicado: (2019)

The Role of Osimertinib in Treatment Naïve Epidermal Growth Factor Receptor–Mutated Stage IIIB or IV Non–Small-Cell Lung Cancer Patients
por: Uprety, Dipesh, et al.
Publicado: (2018)

Optimized Alectinib Dose Regimen for Treatment of Patients With ALK‐Positive Non‐Small Cell Lung Cancer Based on Robust Pharmacometric Analyses and Clinical Evidence
por: Frey, Nicolas, et al.
Publicado: (2021)

Post-GWAS knowledge gap: the how, where, and when
por: Pierce, Steven E., et al.
Publicado: (2020)

Testing for ROS1 in non-small cell lung cancer: a review with recommendations
por: Bubendorf, Lukas, et al.
Publicado: (2016)

How to build segregation complexes in bacteria: Use bridges
por: Funnell, Barbara E.
Publicado: (2014)

Cancer Stem Cells Therapeutic Target Database: The First Comprehensive Database for Therapeutic Targets of Cancer Stem Cells
por: Hu, Xiaoqing, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_vm9nlsruphsvmgme838j1ugpti